One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Veracyte logo
Veracyte VCYT
$ 23.51 -55.06%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Veracyte Financial Statements 2025-2010 | VCYT

Annual Financial Statements Veracyte

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

3.04 B 2.96 B 1.71 B 1.68 B 2.8 B 3.11 B 1.23 B 654 M 220 M 214 M 168 M 175 M 61.6 M - - -

Shares

78.6 M 76.5 M 72.6 M 71.5 M 67.9 M 54.9 M 46.1 M 37 M 33.9 M 28.8 M 25.9 M 21.6 M 4.16 M - - -

Historical Prices

38.7 38.7 23.5 23.5 41.2 48.9 27.9 12.6 6.53 7.74 7.2 9.66 14.5 - - -

Net Income

66.4 M 24.1 M -74.4 M -36.6 M -75.6 M - -12.6 M -23 M -31 M -31.4 M -33.7 M -29.4 M -25.6 M -18.6 M -14.4 M -

Revenue

517 M 446 M 361 M 297 M 220 M 117 M 120 M 92 M 72 M 65.1 M 49.5 M 38.2 M 21.9 M 11.6 M 2.64 M -

Cost of Revenue

- - - - - - 36.1 M 33.1 M 28.2 M 25.5 M 21.5 M 16.6 M 12.6 M 7.58 M 2.92 M -

Gross Profit

363 M 298 M 230 M 176 M - 76 M 83.8 M 58.9 M 43.8 M 39.6 M 28 M 21.6 M 9.28 M 4.04 M -280 K -

Operating Income

57.8 M 16.1 M -85.8 M -41.1 M -81.9 M -35.4 M -15.1 M -22.2 M -26.5 M -28.8 M -33.5 M -29 M -23.2 M -18.9 M -15.3 M -

Interest Expense

10.4 M 9.6 M 9.18 M 4.65 M 254 K 229 K 677 K 1.96 M 4.94 M 2.76 M 378 K 439 K 233 K 280 K 819 K -

EBITDA

79.2 M 39.6 M -58.6 M -15.2 M -62.3 M -27.4 M -12.3 M -19.5 M -23.4 M -27.7 M -32.7 M -27.8 M -22.2 M -18.2 M -14.7 M -

Operating Expenses

305 M 282 M 315 M 217 M 81.9 M 153 M 99 M 81.2 M 70.3 M 68.4 M 61.5 M 50.6 M 32.4 M 23 M 15 M -

General and Administrative Expenses

111 M 111 M 86.2 M 73.2 M 101 M 35.2 M 27.6 M 22.3 M 30.3 M 32 M 29.7 M 24.2 M 12.1 M 7.92 M 5.37 M -

All numbers in USD currency

Quarterly Income Statement Veracyte

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

80.5 M 80 M 79.5 M 200 K 78.7 M 78.4 M 78 M 377 K 77 M 76.5 M 74.8 M 156 K 72.8 M 72.5 M 72.5 M 93.2 K 71.7 M 71.5 M 71.2 M 1.07 M 69.7 M 67.3 M 63.3 M 58 M 54.9 M 50.2 M 49.8 M 49.1 M 48.6 M 45.6 M 41.2 M 40.7 M 38.6 M 34.3 M 34.3 M 35.1 M 33.9 M 33.9 M 33.8 M 31.7 M 27.9 M 27.9 M 27.8 M 27.7 M 27.6 M 26 M 22.5 M 22.5 M 21.6 M 21.2 M 21.1 M 13.9 M 956 K 862 K 763 K 665 K 659 K 653 K 624 K - - - -

Net Income

31.5 M 25.5 M 28.7 M 41.1 M 19.1 M -980 K 7.05 M 5.11 M 15.2 M 5.73 M -1.86 M -28.3 M -29.6 M -8.4 M -8.4 M -3.84 M -8.72 M -9.53 M -14.5 M -10.5 M -14.1 M -9.04 M -41.9 M -8.04 M -4.12 M -11 M -11.7 M -7.46 M -730 K -2.49 M -1.92 M -3.1 M -4.47 M -6.25 M -9.18 M -8.44 M -7.05 M -7.3 M -8.22 M -4.4 M -5.64 M -11.2 M -10.1 M -8.01 M -8.94 M -9.14 M -7.61 M -8.14 M -7.9 M -6.66 M -6.67 M -5.89 M -6.3 M -6.49 M -6.9 M -4.84 M -4.94 M -4.63 M -4.25 M - - - -

Revenue

152 M 150 M 139 M 141 M 132 M 130 M 114 M 119 M 116 M 114 M 96.8 M 98.2 M 90.1 M 90.3 M 90.3 M 80.3 M 75.6 M 72.9 M 67.8 M 67.3 M 60.4 M 55.1 M 36.7 M 34.5 M 31.1 M 20.7 M 31.1 M 29.7 M 31 M 30.1 M 29.5 M 25.8 M 23.5 M 22.8 M 20 M 19.6 M 17.5 M 18.4 M 16.4 M 18.3 M 18.6 M 14.7 M 13.6 M 14 M 12.3 M 11.9 M 11.2 M 12.2 M 9.84 M 8.68 M 7.48 M 6.84 M 5.59 M 5.07 M 4.38 M 4.46 M 3.22 M 2.48 M 1.47 M - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - 9.67 M 9.11 M 8.78 M 8.51 M 8.7 M 8.26 M 8.25 M 7.87 M 7.77 M 7.17 M 6.96 M 6.3 M 6.52 M 6.37 M 6.3 M 6.28 M 6.18 M 5.62 M 5.14 M 4.57 M 4.86 M 4.17 M 3.97 M 3.61 M 3.47 M 3.13 M 3.23 M 2.77 M - 1.98 M - - - - - -

Gross Profit

107 M 109 M 101 M 102 M 91.3 M 89.8 M 79.5 M 78.8 M 79 M 77.9 M 62.5 M 64.8 M 57.7 M 55.8 M 55.8 M - - - - - - - - - - - - 20.1 M 21.9 M 21.4 M 21 M 17 M 15.2 M 14.5 M 12.2 M 11.8 M 10.4 M 11.4 M 10.1 M 11.7 M 12.2 M 8.37 M 7.27 M 7.87 M 6.72 M 6.77 M 6.65 M 7.33 M 5.67 M 4.71 M 3.87 M 3.37 M 2.46 M - - - - - - - - - -

Operating Income

16.6 M 23 M 22.6 M 37.2 M 22.9 M -5.27 M 2.9 M 4.18 M 12 M 4.61 M -4.66 M -35.5 M -31.7 M -8.05 M -8.05 M -5.42 M -9.68 M -10.7 M -15.2 M -12.3 M -16.7 M -7.47 M -45.4 M -8.07 M -4.07 M -11.1 M -12.2 M -8.2 M -1.76 M -3.1 M -2.07 M -3.06 M -4.3 M -5.92 M -8.96 M -6.04 M -6.37 M -6.61 M -7.52 M -3.67 M -4.89 M -10.5 M -9.75 M -7.95 M -8.89 M -9.07 M -7.55 M -8.06 M -7.81 M -6.56 M -6.58 M -5.76 M -6.1 M -5.42 M -5.89 M - -4.94 M - - - - - -

Interest Expense

4.55 M 3.54 M 7.33 M 3.44 M -4.06 M 6.52 M 4.52 M -732 K 4.83 M 2.76 M 2.75 M 5.04 M 1.97 M -226 K -226 K 1.98 M 805 K 1.09 M 784 K 1.02 M 1.2 M -1.72 M -248 K 28 K -58 K 91 K 539 K 143 K 1.09 M 841 K 453 K 488 K 333 K 150 K 226 K 123 K 134 K 119 K 100 K 75 K 48 K 36 K 43 K 47 K 35 K 28 K 32 K 18 K 23 K 19 K 12 K -28 K -76 K 5 K -1 M - 1 K - - - - - -

EBITDA

20.3 M 26.2 M 25.9 M 40.6 M 26.2 M -1.97 M 6.1 M 7.78 M 15.8 M 8.41 M -956 K -30.9 M -26.4 M -2.75 M -2.75 M -110 K -4.47 M -5.34 M -9.76 M -6.86 M -11.7 M -3.75 M -43.6 M -6.8 M -2.79 M -9.78 M -10.9 M -7.6 M -1.5 M -2.83 M -1.8 M -2.79 M -4.04 M -5.65 M -8.69 M -5.74 M -6.1 M -6.34 M -7.25 M -3.37 M -4.62 M -10.2 M -9.48 M -7.68 M -8.62 M -8.81 M -7.2 M -8.89 M -7.52 M -6.28 M -6.31 M -5.48 M -5.38 M -4.99 M -5.7 M - -4.41 M - - - - - -

Operating Expenses

90.5 M 85.6 M 78.5 M 64.8 M 68.3 M 95 M 76.6 M 74.6 M 67 M 73.3 M 67.1 M 100 M 89.4 M - 63.9 M 5.42 M 9.68 M 10.7 M 15.2 M 12.3 M 16.7 M 7.47 M 45.4 M 8.07 M 4.07 M 11.1 M 12.2 M 28.3 M 23.6 M 24.5 M 23.1 M 20.1 M 19.5 M 20.4 M 21.1 M 17.9 M 16.7 M 18.1 M 17.7 M 15.4 M 17.1 M 18.9 M 17 M 22 M 21.2 M 21 M 18.8 M 20.3 M 17.6 M 15.2 M 14.1 M 12.6 M 11.7 M 10.5 M 10.3 M - 8.16 M - - - - - -

General and Administrative Expenses

29.3 M 27.4 M 23.7 M 17.4 M 27.3 M 32.3 M 33.8 M 26.9 M 25.7 M 31.7 M 26.2 M 23.8 M 16.3 M 25 M 25 M 18.2 M 17.6 M 19.8 M 20.9 M 18.8 M 20.7 M 15.5 M 46.3 M 12.4 M 8.55 M 7.96 M 7.81 M 8.58 M 6.62 M 6.92 M 6.9 M 6.64 M 5.74 M 5.93 M 5.64 M 5.36 M 5.52 M 6.19 M 6.02 M 5.72 M 5.76 M 6.07 M 6.23 M 5.52 M 5.73 M 5.54 M 5.8 M 5.23 M 5.72 M 3.93 M 3.98 M 3.33 M 3.24 M 2.74 M 2.79 M - 2.1 M - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Veracyte VCYT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Veracyte plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Keros Therapeutics Keros Therapeutics
KROS
$ 9.42 -13.02 % $ 351 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 7.13 -11.76 % $ 109 M australiaAustralia
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 2.32 -9.38 % $ 588 M usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.98 -4.85 % $ 226 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 298.8 -5.48 % $ 5.78 B usaUSA
Longeveron Longeveron
LGVN
$ 1.76 -1.12 % $ 30.9 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 366.97 -3.62 % $ 1.23 T usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.01 -5.2 % $ 48.9 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.94 -4.68 % $ 181 M israelIsrael
Liquidia Corporation Liquidia Corporation
LQDA
$ 44.46 -6.16 % $ 3.83 B usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 17.5 -7.77 % $ 1.75 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 4.46 -11.84 % $ 310 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.08 -1.47 % $ 17 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 93.45 -3.63 % $ 4.69 B usaUSA
MediciNova MediciNova
MNOV
$ 1.46 0.68 % $ 71.6 M usaUSA
Monopar Therapeutics Monopar Therapeutics
MNPR
$ 68.33 -6.15 % $ 506 M usaUSA
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.8 -1.41 % $ 1.37 B franceFrance
Vericel Corporation Vericel Corporation
VCEL
$ 51.31 12.82 % $ 2.58 B usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 1.75 -6.68 % $ 103 M usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 10.24 26.11 % $ 131 M usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
$ 13.33 -6.13 % $ 363 M israelIsrael
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 36.18 -5.98 % $ 610 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.28 -7.25 % $ 25.8 M usaUSA
Zoetis Zoetis
ZTS
$ 81.84 -8.23 % $ 36.3 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 11.12 -9.67 % $ 1.21 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Novartis AG Novartis AG
NVS
$ 161.95 -1.85 % $ 314 B schweizSchweiz
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Ocugen Ocugen
OCGN
$ 0.81 -7.94 % $ 253 M usaUSA
Omeros Corporation Omeros Corporation
OMER
$ 17.05 -6.08 % $ 1.08 B usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 0.45 5.32 % $ 43.1 M canadaCanada
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 8.47 -9.37 % $ 744 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.91 -5.45 % $ 162 M israelIsrael
Puma Biotechnology Puma Biotechnology
PBYI
$ 9.88 -7.58 % $ 494 M usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.17 -10.0 % $ 54.3 M usaUSA
Pfizer Pfizer
PFE
$ 30.03 -2.47 % $ 171 B usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 12.53 0.56 % $ 8.63 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 5.07 -10.83 % $ 370 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 0.81 -4.85 % $ 49.7 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA